Kyros Therapeutics (India) Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 1.65 M
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 0.79 M
About Kyros Therapeutics (India)
Kyros Therapeutics (India) Limited (KTIL) is a Public Limited Indian Non-Government Company incorporated in India on 30 March 2005 and has a history of 19 years and ten months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.65 M.
The company currently has active open charges totaling ₹0.79 M.
Pankaj Vyas, Debendranath Sarangi, and Venkateswara Tattugolla serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24239TG2005PLC045761
- Company No.
045761
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2005
- Date of AGM
30 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Kyros Therapeutics (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Vyas  | Additional Director | 13-Jul-2011 | Current |
| Debendranath Sarangi | Additional Director | 04-Aug-2011 | Current |
| Venkateswara Tattugolla | Additional Director | 05-May-2015 | Current |
Financial Performance of Kyros Therapeutics (India).
Enhance accessibility to Kyros Therapeutics (India)'s financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kyros Therapeutics (India)?
Unlock access to Kyros Therapeutics (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.79 M
₹0
Charges Breakdown by Lending Institutions
- The Karur Vysya Bank Limited : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2013 | The Karur Vysya Bank Limited | ₹0.27 M | Open |
| 30 Dec 2011 | The Karur Vysya Bank Limited | ₹0.53 M | Open |
How Many Employees Work at Kyros Therapeutics (India)?
Unlock and access historical data on people associated with Kyros Therapeutics (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kyros Therapeutics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kyros Therapeutics (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
